

Retail Research

Lew Chee Hao, CMT

lew.chee-hao@ambankgroup.com +603-2036 2300

17 October 2025

OPTIMAX HOLDINGS (OPTIMAX | 0222)

Last Price: RM0.695 | Technical Call: BUY | Target Price: RM0.85



Bursa Code: OPTIMAX, 0222	Support 1: RM0.68	Entry: RM0.68–0.695
Sector: Health Care	Support 2: RM0.65	Target: RM0.80, RM0.85
Market Cap: RM378mil	Resistance 1: RM0.80	Exit: RM0.64
Shariah Compliant: Yes	Resistance 2: RM0.85	

Company Profile. Optimax Holdings is a leading private eye specialist services provider in Malaysia, offering comprehensive eye care through a nationwide network of 25 centres, comprising a specialist hospital, 16 ambulatory care centres (ACCs), and 8 satellite clinics. The group provides a full range of ophthalmic services, including cataract surgery, refractive procedures (such as LASIK and SMILE), treatment of eye diseases, oculoplastic surgery, and general eye examinations. In addition, Optimax has diversified beyond ophthalmology to include aesthetic and plastic surgery services, as well as optical retail and dispensing.

Growth Strategies. (i) Expanding network and capacity through new ACCs, satellite clinics, and eye hospitals (e.g. Kempas, Setia Alam) across Malaysia and key regional markets (Cambodia, Indonesia, Vietnam) to increase surgical capacity and capture growing medical tourism demand. (ii) Enhancing high-margin, technology-driven services by prioritising advanced refractive surgeries (e.g. SMILE, ZEISS Smile Pro) to improve margins, and introducing new technologies (e.g. Presbyond) to attract emerging patient segments and elevate service offerings. (iii) Driving operational leverage and margin expansion by maximising utilisation of existing centres and improving marketing efficiency through targeted digital campaigns and overseas patient acquisition initiatives.

Financial Performance. In 1HFY25, Optimax posted higher revenue of RM64.4mil (+6.9% YoY) and PAT of RM7.6mil (+11.9% YoY), mainly due to effective marketing efforts from ongoing promotions on online platforms and contributions from newly established satellite clinics/centres in East Malaysia and Cambodia.

Valuation. Optimax is trading at an FY25F P/E of 23x, lower than the Bursa Healthcare Index's P/E of 34x. In comparison, Topvision Eye Specialist — which is principally involved in ophthalmology and related medical consultancy services, and operates ambulatory surgical centres in Malaysia — trades at a higher annualised FY25F P/E of 25x.

Technical Analysis. Optimax broke out of its 3-week bullish pennant pattern two sessions ago, suggesting that its previous uptrend may have resumed. With the stock trading near its 52-week high and supported by rising EMAs, further strength may be seen in the coming sessions. A bullish bias may emerge above the RM0.68 level, with stop-loss set at RM0.64, below the 21-day EMA. Towards the upside, near-term resistance level is seen at RM0.80, followed by RM0.85.

Stock on Radar 17 October 2025

DISCLOSURE AND DISCLAIMER

This report is prepared for information purposes only and it is issued by AmInvestment Bank Berhad ("AmInvestment") without regard to your individual financial circumstances and objectives. Nothing in this report shall constitute an offer to sell, warranty, representation, recommendation, legal, accounting or tax advice, solicitation, or expression of views to influence any one to buy or sell any real estate, securities, stocks, foreign exchange, futures, investment or other products. AmInvestment recommends that you evaluate a particular investment or strategy based on your individual circumstances and objectives and/or seek financial, legal, or other advice on the appropriateness of the particular investment or strategy.

The information in this report was obtained or derived from sources that AmInvestment believes are reliable and correct at the time of issue. While all reasonable care has been taken to ensure that the stated facts are accurate and views are fair and reasonable, AmInvestment has not independently verified the information and does not warrant or represent that they are accurate, adequate, complete, or up-to-date and they should not be relied upon as such. All information included in this report constitute AmInvestment's views as of this date and are subject to change without notice. Notwithstanding that, AmInvestment has no obligation to update its opinion or information in this report. Facts and views presented in this report may not reflect the views of or information known to other business units of AmInvestment's affiliates and/or related corporations (collectively, "AmBank Group").

This report is prepared for the clients of AmBank Group and it cannot be altered, copied, reproduced, distributed or republished for any purpose without AmInvestment's prior written consent. AmInvestment, AmBank Group and its respective directors, officers, employees, and agents ("Relevant Person") accept no liability whatsoever for any direct, indirect, or consequential losses, loss of profits and/or damages arising from the use or reliance of this report and/or further communications given in relation to this report. Any such responsibility is hereby expressly disclaimed.

AmInvestment is not acting as your advisor and does not owe you any fiduciary duties in connection with this report. The Relevant Person may provide services to any company and affiliates of such companies in or related to the securities or products and/or may trade or otherwise effect transactions for their own account or the accounts of their customers which may give rise to real or potential conflicts of interest.

This report is not directed to or intended for distribution or publication outside Malaysia. If you are outside Malaysia, you should have regard to the laws of the jurisdiction in which you are located.

If any provision of this disclosure and disclaimer is held to be invalid in whole or in part, such provision will be deemed not to form part of this disclosure and disclaimer. The validity and enforceability of the remainder of this disclosure and disclaimer will not be affected.